Startup profile · funding coverage
Fidocure
Precision oncology platform matching canine cancer to targeted therapies via genomic testing.
Stage
series a
Status
private
Coverage
full
Why Fidocure is interesting
FidoCure brings human-grade cancer genomics to veterinary oncology — Lerer Hippeau joined a16z in seed and Series A rounds.
Key facts
- Seed (Jan 2019): $5M led by a16z Bio (/fund/andreessen-horowitz); Lerer Hippeau (/fund/lerer-hippeau), Y Combinator participated (TechCrunch)
- Series A (Oct 2020): $10M led by Polaris; a16z and Lerer Hippeau re-upped (PR Newswire)
- Product: genomic testing to match canine cancer to targeted therapies
Investors in our directory
Funds linked from Fidocure's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences Healthtech
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Fidocure's financing or category context.
FAQs about Fidocure
Funding context and why this company shows up in venture coverage.
FidoCure is a precision oncology platform for dogs that uses genomic testing to match canine cancer patients with targeted therapies — applying human-grade cancer genomics to veterinary medicine.
FidoCure's seed ($5M, 2019) was led by a16z Bio (/fund/andreessen-horowitz) with Lerer Hippeau (/fund/lerer-hippeau). Its $10M Series A (2020) included both firms re-upping.
FidoCure is at Series A based on its October 2020 $10M round. No later round has been publicly disclosed as of July 2026.
Canine cancer treatment often relies on trial-and-error chemotherapy. FidoCure applies precision oncology — genomic matching to targeted drugs — in a market with limited veterinary options.
No. FidoCure remains a private company.
Last updated: 2026-07-24